September 12, 2005 10:29 ET

Lancet Article Features Potential Use of Statins to Treat Alzheimer's Disease

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 12, 2005) -

Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

The potential use of statins to treat Alzheimer's disease (AD) is featured in the current issue of The Lancet Neurology (Sept. 2005;4: 521-2). The article concludes that statins, which are used to lower cholesterol levels, may be useful in the prevention or delaying onset of AD, in treating the symptoms of AD, and in slowing disease progression. The article's authors were M. Kivipelto, A. Solomon, and B. Winblad from the Karolinska University Hospital in Stockholm, Sweden.

According to the article, "Delaying of the disease process would be of great clinical and public-health importance. Statins may be useful both in the prevention or delaying of onset, in treating the symptoms, and in slowing the progression." Further trials are needed before statins can be officially recommended for AD treatment, and such trials are currently ongoing.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

The potential for the use of statin drugs to treat or reduce the risk of Alzheimer's disease has also been featured in general media such as New York Times (April 13, 2004), Fortune magazine (August 9, 2004), Newsweek magazine (Jan 19, 2004), Los Angeles Times (June 22, 2003), and The Wall Street Journal (April 17 and 18, 2002).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX